MX2021002028A - Metodos y composiciones para farmacos para tratar enfermedades oftalmicas. - Google Patents
Metodos y composiciones para farmacos para tratar enfermedades oftalmicas.Info
- Publication number
- MX2021002028A MX2021002028A MX2021002028A MX2021002028A MX2021002028A MX 2021002028 A MX2021002028 A MX 2021002028A MX 2021002028 A MX2021002028 A MX 2021002028A MX 2021002028 A MX2021002028 A MX 2021002028A MX 2021002028 A MX2021002028 A MX 2021002028A
- Authority
- MX
- Mexico
- Prior art keywords
- retinal
- diseases
- ocular
- limitation
- eye
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 206010046851 Uveitis Diseases 0.000 abstract 3
- 230000037390 scarring Effects 0.000 abstract 3
- 208000002691 Choroiditis Diseases 0.000 abstract 2
- 208000003971 Posterior uveitis Diseases 0.000 abstract 2
- 208000015181 infectious disease Diseases 0.000 abstract 2
- 230000002458 infectious effect Effects 0.000 abstract 2
- 208000027866 inflammatory disease Diseases 0.000 abstract 2
- 208000031104 Arterial Occlusive disease Diseases 0.000 abstract 1
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 abstract 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 208000009329 Graft vs Host Disease Diseases 0.000 abstract 1
- 206010022557 Intermediate uveitis Diseases 0.000 abstract 1
- 206010022941 Iridocyclitis Diseases 0.000 abstract 1
- 201000006165 Kuhnt-Junius degeneration Diseases 0.000 abstract 1
- 206010065062 Meibomian gland dysfunction Diseases 0.000 abstract 1
- 208000022873 Ocular disease Diseases 0.000 abstract 1
- 208000004788 Pars Planitis Diseases 0.000 abstract 1
- 206010034277 Pemphigoid Diseases 0.000 abstract 1
- 201000007737 Retinal degeneration Diseases 0.000 abstract 1
- 208000017442 Retinal disease Diseases 0.000 abstract 1
- 208000032430 Retinal dystrophy Diseases 0.000 abstract 1
- 208000014139 Retinal vascular disease Diseases 0.000 abstract 1
- 206010038910 Retinitis Diseases 0.000 abstract 1
- 206010039705 Scleritis Diseases 0.000 abstract 1
- 208000000208 Wet Macular Degeneration Diseases 0.000 abstract 1
- 206010064930 age-related macular degeneration Diseases 0.000 abstract 1
- 208000002205 allergic conjunctivitis Diseases 0.000 abstract 1
- 230000000172 allergic effect Effects 0.000 abstract 1
- 201000004612 anterior uveitis Diseases 0.000 abstract 1
- 208000021328 arterial occlusion Diseases 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 abstract 1
- 201000004709 chorioretinitis Diseases 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- 208000011325 dry age related macular degeneration Diseases 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- 208000024908 graft versus host disease Diseases 0.000 abstract 1
- 201000004614 iritis Diseases 0.000 abstract 1
- 206010023332 keratitis Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 201000007407 panuveitis Diseases 0.000 abstract 1
- 230000004258 retinal degeneration Effects 0.000 abstract 1
- 230000002207 retinal effect Effects 0.000 abstract 1
- 208000004644 retinal vein occlusion Diseases 0.000 abstract 1
- 208000018464 vernal keratoconjunctivitis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862719938P | 2018-08-20 | 2018-08-20 | |
| PCT/US2019/047309 WO2020041344A1 (en) | 2018-08-20 | 2019-08-20 | Methods and compositions for drugs to treat ophthalmic diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021002028A true MX2021002028A (es) | 2021-07-21 |
Family
ID=69591159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021002028A MX2021002028A (es) | 2018-08-20 | 2019-08-20 | Metodos y composiciones para farmacos para tratar enfermedades oftalmicas. |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US12221447B2 (enExample) |
| EP (1) | EP3840745A4 (enExample) |
| JP (1) | JP2021534202A (enExample) |
| KR (1) | KR20210049857A (enExample) |
| CN (1) | CN112654353A (enExample) |
| AU (1) | AU2019326448A1 (enExample) |
| BR (1) | BR112021003189A2 (enExample) |
| CA (1) | CA3109809A1 (enExample) |
| CO (1) | CO2021003607A2 (enExample) |
| IL (1) | IL280952A (enExample) |
| MX (1) | MX2021002028A (enExample) |
| SG (1) | SG11202101522WA (enExample) |
| TW (1) | TW202021968A (enExample) |
| WO (1) | WO2020041344A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3109809A1 (en) | 2018-08-20 | 2020-02-27 | Duke University | Methods and compositions for drugs to treat ophthalmic diseases |
| JP7706671B2 (ja) * | 2023-06-16 | 2025-07-11 | 千寿製薬株式会社 | 眼疾患モデル動物 |
| JP7776899B1 (ja) * | 2024-06-14 | 2025-11-27 | 株式会社坪田ラボ | 局所投与用の重症眼表面疾患の処置剤 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4153693B2 (ja) * | 2001-04-25 | 2008-09-24 | 大日本住友製薬株式会社 | 新規なＣａＭＫＫ阻害剤 |
| GB0600763D0 (en) * | 2006-01-13 | 2006-02-22 | Crysoptix Ltd | 6, 7-dihydrobenzimidazo[1,2-C]quininazolin-6-one carboxylic acid, its esters and method of synthesis thereof |
| GB0600764D0 (en) * | 2006-01-13 | 2006-02-22 | Crysoptix Ltd | Organic compound, optical crystal film and method of production thereof |
| WO2008045273A2 (en) | 2006-10-12 | 2008-04-17 | Duke University | Camkk(beta) as a target for treating obesity |
| JP5464395B2 (ja) | 2008-02-01 | 2014-04-09 | 大陽日酸株式会社 | 重水素化された芳香環又は複素環を有する化合物の製造方法 |
| US8354557B2 (en) | 2008-06-17 | 2013-01-15 | Concert Pharmaceuticals, Inc. | Synthesis of deuterated morpholine derivatives |
| US8704001B2 (en) | 2008-09-16 | 2014-04-22 | Concert Pharmaceuticals, Inc. | Deuterated 2-amino-3-hydroxypropanoic acid derivatives |
| US20130253035A1 (en) | 2010-08-16 | 2013-09-26 | Duke University | Camkk-beta as a target for treating cancer |
| US8895118B2 (en) * | 2010-11-09 | 2014-11-25 | Crysoptix K.K. | Negative dispersion retardation plate and achromatic circular polarizer |
| SG194625A1 (en) | 2011-05-23 | 2013-12-30 | Sanofi Sa | Process for the preparation of deuterated compounds containing n-alkyl groups |
| EP4345100A3 (en) | 2012-09-18 | 2024-04-10 | Auspex Pharmaceuticals, Inc. | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| CA2895846A1 (en) | 2012-12-20 | 2014-06-26 | Concert Pharmaceuticals, Inc. | Deuterated alk inhibitors |
| US9447132B2 (en) | 2013-04-12 | 2016-09-20 | Achillion Pharmaceuticals, Inc. | Highly active nucleoside derivative for the treatment of HCV |
| JP6408569B2 (ja) | 2013-10-17 | 2018-10-17 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | Ｄｎａ−ｐｋ阻害剤としての（ｓ）−ｎ−メチル−８−（１−（（２’−メチル−［４，５’−ビピリミジン］−６−イル）アミノ）プロパン−２−イル）キノリン−４−カルボキサミドおよびその重水素化誘導体の共結晶 |
| CA3109809A1 (en) | 2018-08-20 | 2020-02-27 | Duke University | Methods and compositions for drugs to treat ophthalmic diseases |
-
2019
- 2019-08-20 CA CA3109809A patent/CA3109809A1/en active Pending
- 2019-08-20 KR KR1020217008504A patent/KR20210049857A/ko not_active Ceased
- 2019-08-20 MX MX2021002028A patent/MX2021002028A/es unknown
- 2019-08-20 AU AU2019326448A patent/AU2019326448A1/en not_active Abandoned
- 2019-08-20 US US17/269,830 patent/US12221447B2/en active Active
- 2019-08-20 CN CN201980054524.XA patent/CN112654353A/zh active Pending
- 2019-08-20 BR BR112021003189-8A patent/BR112021003189A2/pt not_active Application Discontinuation
- 2019-08-20 SG SG11202101522WA patent/SG11202101522WA/en unknown
- 2019-08-20 JP JP2021509910A patent/JP2021534202A/ja active Pending
- 2019-08-20 TW TW108129703A patent/TW202021968A/zh unknown
- 2019-08-20 EP EP19852526.3A patent/EP3840745A4/en active Pending
- 2019-08-20 WO PCT/US2019/047309 patent/WO2020041344A1/en not_active Ceased
-
2021
- 2021-02-18 IL IL280952A patent/IL280952A/en unknown
- 2021-03-19 CO CONC2021/0003607A patent/CO2021003607A2/es unknown
-
2024
- 2024-12-09 US US18/973,967 patent/US20250122209A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3109809A1 (en) | 2020-02-27 |
| US12221447B2 (en) | 2025-02-11 |
| EP3840745A4 (en) | 2022-06-08 |
| KR20210049857A (ko) | 2021-05-06 |
| EP3840745A1 (en) | 2021-06-30 |
| JP2021534202A (ja) | 2021-12-09 |
| BR112021003189A2 (pt) | 2021-05-11 |
| CO2021003607A2 (es) | 2021-07-30 |
| WO2020041344A4 (en) | 2020-03-26 |
| US20210198266A1 (en) | 2021-07-01 |
| SG11202101522WA (en) | 2021-03-30 |
| US20250122209A1 (en) | 2025-04-17 |
| AU2019326448A1 (en) | 2021-03-11 |
| IL280952A (en) | 2021-04-29 |
| WO2020041344A1 (en) | 2020-02-27 |
| CN112654353A (zh) | 2021-04-13 |
| TW202021968A (zh) | 2020-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021002028A (es) | Metodos y composiciones para farmacos para tratar enfermedades oftalmicas. | |
| RU2009145939A (ru) | Профилактическое или терапевтическое средство, применяемое при заболеваниях заднего отдела глаза | |
| CA2806942C (en) | Compounds for the treatment/prevention of ocular inflammatory diseases | |
| RU2014123472A (ru) | Производные 4-прегенен-11ss-17-21-триол-3,20-диона для лечения глазных болезней | |
| JP2015134824A5 (enExample) | ||
| RU2005118107A (ru) | Ингибиторы гистондеацетилазы для лечения офтальмологических неоваскулярных или отечных нарушений и заболеваний | |
| WO2017158365A3 (en) | Ophthalmic delivery device and ophthalmic active agent containing compositions | |
| JPWO2010010702A1 (ja) | 軸性近視の予防または治療剤 | |
| MD3676G2 (ro) | Dispozitiv şi metodă de tratament al cataractei senile | |
| KR20130052619A (ko) | 방부제가 없는 비마토프로스트 및 티몰롤 용액 | |
| Mohlin et al. | The link between morphology and complement in ocular disease | |
| CA2582316A1 (en) | Use of inhibitors of jun n-terminal kinases for the treatment of glaucomatous retinopathy and ocular diseases | |
| MX2021005352A (es) | Tratamiento y diagnóstico de enfermedades oculares mediadas por autoanticuerpos. | |
| JP2013537551A5 (enExample) | ||
| JP2016522830A5 (enExample) | ||
| WO2009089399A2 (en) | Compositions comprising toll-like receptor or coreceptor antagonists and methods for ocular neuroprotection | |
| WO2008152507A3 (en) | Compositions and methods for treating ophthalmic disorders | |
| JP2013513606A5 (enExample) | ||
| RU2003124369A (ru) | Способ лечения макулярного разрыва | |
| CA2817505C (en) | Pharmaceutical formulation having neuroprotective activity | |
| Uno | Ocular Mycosis. | |
| Arevalo et al. | Macular hole after LASIK | |
| MY145266A (en) | Pharmaceutical use of cox-2 inhibitors in angiogenesis-mediated ocular disorders | |
| JP2013523892A (ja) | 視覚障害を処置するための組成物および方法 | |
| MA53146B1 (fr) | Procédé de préparation de suspensions aqueuses ophtalmiques stériles de nanocristaux de forme a de propionate de fluticasone |